← Back to Clinical Trials
Recruiting NCT07318987

NCT07318987 EFFECT OF SAPHENOUS NERVE RELEASE ON PATIENTS WITH PATELLOFEMORAL PAIN SYNDROME

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07318987
Status Recruiting
Phase
Sponsor Cairo University
Condition Patellofemoral Pain Syndrome
Study Type INTERVENTIONAL
Enrollment 36 participants
Start Date 2025-10-10
Primary Completion 2026-01-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 35 Years
Study Type INTERVENTIONAL
Interventions
Saphenous nerve release

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 36 participants in total. It began in 2025-10-10 with a primary completion date of 2026-01-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patellofemoral Pain Syndrome (PFPS) is a frequent cause of anterior knee pain in young, physically active individuals, especially females, and is commonly managed with quadriceps and hip-focused exercises. However, the role of neural factors has been largely overlooked. The saphenous nerve, which supplies sensation to the anteromedial knee, may become irritated or entrapped and contribute to pain and neuromuscular dysfunction in PFPS. This study suggests that manual therapy targeting the saphenous nerve could improve pain, function, and balance, providing a more holistic approach to PFPS rehabilitation.

Eligibility Criteria

Inclusion Criteria: 1 - Age from 18 to 35 and BMI 18 to 25 kg/m2. 2. Both gender (male and female) 3. Patients who had anterior knee pain for at least six weeks 4. Patients with positive saphenous neurodynamic test (SAPHNT) Exclusion Criteria: 1. Knee replacement 2. An intraarticular injection within the past 3 months 3. Previous operative treatment or arthroscopy, other secondary knee-related problems (bursitis, tendinopathy, osteochondritis, neuromas, intraarticular pathology (such as osteoarthritis), tumor, and rheumatologic diseases 4. Diabetic neuropathic pain or fibromyalgia

Contact & Investigator

Central Contact

Markos Boshra, bachelor's

✉ markosboshra3@gmail.com

📞 01201365245

Frequently Asked Questions

Who can join the NCT07318987 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Patellofemoral Pain Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07318987 currently recruiting?

Yes, NCT07318987 is actively recruiting participants. Contact the research team at markosboshra3@gmail.com for enrollment information.

Where is the NCT07318987 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07318987 clinical trial?

NCT07318987 is sponsored by Cairo University. The trial plans to enroll 36 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology